MedPath

Dexamethasone

Generic Name
Dexamethasone
Brand Names
Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper
Drug Type
Small Molecule
Chemical Formula
C22H29FO5
CAS Number
50-02-2
Unique Ingredient Identifier
7S5I7G3JQL
Background

Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.

Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.

Indication

Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.

Associated Conditions
Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes
Associated Therapies
-

Comparison of the Efficacy of Different Steroids in the Treatment of Abnormal Scars (Keloids, Hypertrophic Scars)

First Posted Date
2020-10-20
Last Posted Date
2020-10-20
Lead Sponsor
Tel-Aviv Sourasky Medical Center
Target Recruit Count
40
Registration Number
NCT04593706

Romiplostim, Rituximab and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia

Phase 2
Conditions
Immune Thrombocytopenia
Thrombotic Thrombocytopenic Purpura
Interventions
First Posted Date
2020-10-19
Last Posted Date
2020-10-19
Lead Sponsor
David Gomez Almaguer
Target Recruit Count
12
Registration Number
NCT04588194
Locations
🇲🇽

Servicio de Hematología, Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico

Efficacy of a Single Dose Dexamethasone in Reducing the Postembolization Syndrome in Men Undergoing Prostatic Artery Embolization for Benign Prostatic Hyperplasia

Phase 4
Conditions
Prostatic Hyperplasia
Interventions
First Posted Date
2020-10-19
Last Posted Date
2022-03-22
Lead Sponsor
Rigshospitalet, Denmark
Target Recruit Count
60
Registration Number
NCT04588857
Locations
🇩🇰

Rigshospitalet, Copenhagen, Denmark

A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.

Phase 1
Completed
Conditions
Acute Myeloid Leukemia
Interventions
First Posted Date
2020-10-08
Last Posted Date
2024-06-03
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
59
Registration Number
NCT04580121
Locations
🇮🇹

Ospedale Santa Chiara; Unita Operativa Di Ematologia, Pisa, Toscana, Italy

🇺🇸

UC Davis Comprehensive Cancer Center, Sacramento, California, United States

🇩🇰

Rigshospitalet; Hæmatologisk Klinik, Klinisk Afprøvnings Team KAT, København Ø, Denmark

and more 20 locations

Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma

Phase 1
Active, not recruiting
Conditions
Multiple Myeloma
Interventions
First Posted Date
2020-09-30
Last Posted Date
2024-08-14
Lead Sponsor
AbbVie
Target Recruit Count
40
Registration Number
NCT04570631
Locations
🇫🇷

CHRU Lille - Hopital Claude Huriez /ID# 222302, Lille, Nord, France

🇫🇷

Institut Gustave Roussy /ID# 223951, Villejuif Cedex, Val-de-Marne, France

🇺🇸

Norton Healthcare Pavilion /ID# 222918, Louisville, Kentucky, United States

and more 16 locations

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Phase 3
Recruiting
Conditions
RISS Stage I Plasma Cell Myeloma
RISS Stage II Plasma Cell Myeloma
Plasma Cell Myeloma
Interventions
Drug: Bortezomib
Biological: Daratumumab and Hyaluronidase-fihj
Drug: Dexamethasone
Drug: Lenalidomide
Other: Quality-of-Life Assessment
First Posted Date
2020-09-28
Last Posted Date
2024-08-09
Lead Sponsor
ECOG-ACRIN Cancer Research Group
Target Recruit Count
1450
Registration Number
NCT04566328
Locations
🇺🇸

Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States

🇺🇸

Riverside Methodist Hospital, Columbus, Ohio, United States

🇺🇸

Case Western Reserve University, Cleveland, Ohio, United States

and more 592 locations

Neostigmine and Dexamethasone in Adductor Canal Block

Not Applicable
Completed
Conditions
Pain, Postoperative
Interventions
First Posted Date
2020-09-25
Last Posted Date
2022-07-29
Lead Sponsor
Cairo University
Target Recruit Count
90
Registration Number
NCT04565301
Locations
🇪🇬

Kasr Alainy hospitals, Cairo, Egypt

Fascia Iliaca Block Supplemented With Perineural Vs Intravenous Dexamethasone

Phase 4
Conditions
Postoperative Pain
Interventions
Drug: Dexamethasone
Drug: Placebo
First Posted Date
2020-09-24
Last Posted Date
2020-09-24
Lead Sponsor
Assiut University
Target Recruit Count
99
Registration Number
NCT04561856

The Effects of IV vs Oral Dexamethasone on Postoperative Nausea, Vomiting, and Pain

Phase 4
Completed
Conditions
Nausea and Vomiting, Postoperative
Interventions
First Posted Date
2020-09-24
Last Posted Date
2024-07-22
Lead Sponsor
University of Colorado, Denver
Target Recruit Count
127
Registration Number
NCT04563494
Locations
🇺🇸

Children's Hospital of Colorado, Aurora, Colorado, United States

Study to Evaluate the Efficacy and Safety of EG-009A Compared to DEX in Patients With COVID-19 Pneumonia

Phase 2
Withdrawn
Conditions
COVID-19 Pneumonia
Interventions
Drug: EG-009A Placebo
Drug: EG-009A
Drug: Standard of Care
Drug: Dexamethasone
First Posted Date
2020-09-23
Last Posted Date
2023-07-28
Lead Sponsor
Evergreen Therapeutics, Inc.
Registration Number
NCT04561180
© Copyright 2025. All Rights Reserved by MedPath